Renishaw Granted EU MDR Approval for Medical Devices

Renishaw, a global engineering company pioneering robotic neurosurgical solutions, announces that the company’s neuromate® stereotactic robot, incorporating neuroinspire™ surgical planning software, has received EU Medical Device Regulation (MDR) certification from its Notified Body, the British Standards Institution (BSI).

As one of the first companies to achieve MDR approval, Renishaw reaffirms its commitment to the market, its customers and, most importantly, the patients who will continue to benefit from the use of its products.

In a move that became one of the most significant shifts in European medical device regulations in over two decades, the MDR 2017/745 replaced the European Directives on Medical Devices (AIMDD 90/385/EEC and MDD 93/42/EEC) in May 2021. The goal was to create a more modernised, robust and long-term legislative framework for medical devices, as well as software that is used by those devices, with strict inspection by Notified Bodies to assure the highest levels of safety and health.

The introduction of the MDR 2017/745 means more stringent requirements, particularly in the area of clinical and post-market review data, are in place. As a result, many medical device companies within the EU have had to make significant time and financial investments to improve their current processes to capture and analyse this data.

“Achieving MDR certification is a significant achievement for Renishaw and is the result of months of hard work, dedication and due diligence within our team”, said Nina Sainte-Marie, Operations Manager at Renishaw. “Without this and the early adoption of the new regulatory requirements in Europe, certification would not have been possible. I am especially proud to be part of a team that values quality so highly and is committed to establishing compliance within the new EU regulations.”

Paul Skinner, General Manager at Renishaw, commented: “The replacement of the MDD with the MDR has improved the standards for medical device regulation within Europe and we are delighted to be one of the first neurosurgical solutions companies to receive certification. Not only does it reaffirm our commitment to compliance with the evolving regulatory requirements for medical devices but is testament to our progress in meeting the standards required for approval of the neuromate robot and neuroinspire planning software. Thanks to the Renishaw team we’re able to continue supply within Europe and reach our ultimate goal of ensuring patients have access to life-changing neurosurgical devices.”

SourceRenishaw

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution